- Home
- TELA vs IGMS Comparison
TELA vs IGMS Comparison
Compare TELA & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TELA
- IGMS
- Stock Information
- Founded
- TELA 2012
- IGMS 1993
- Country
- TELA United States
- IGMS United States
- Employees
- TELA N/A
- IGMS N/A
- Industry
- TELA Medical/Dental Instruments
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- TELA Health Care
- IGMS Health Care
- Exchange
- TELA Nasdaq
- IGMS Nasdaq
- Market Cap
- TELA 92.2M
- IGMS 82.1M
- IPO Year
- TELA 2019
- IGMS 2019
- Fundamental
- Price
- TELA $1.24
- IGMS $1.24
- Analyst Decision
- TELA Strong Buy
- IGMS Hold
- Analyst Count
- TELA 4
- IGMS 8
- Target Price
- TELA $6.00
- IGMS $6.14
- AVG Volume (30 Days)
- TELA 425.7K
- IGMS 198.4K
- Earning Date
- TELA 03-20-2025
- IGMS 03-06-2025
- Dividend Yield
- TELA N/A
- IGMS N/A
- EPS Growth
- TELA N/A
- IGMS N/A
- EPS
- TELA N/A
- IGMS N/A
- Revenue
- TELA $69,300,000.00
- IGMS $2,679,000.00
- Revenue This Year
- TELA $38.03
- IGMS $134.71
- Revenue Next Year
- TELA $24.38
- IGMS $74.27
- P/E Ratio
- TELA N/A
- IGMS N/A
- Revenue Growth
- TELA 18.56
- IGMS 25.77
- 52 Week Low
- TELA $1.15
- IGMS $1.15
- 52 Week High
- TELA $6.50
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- TELA 20.75
- IGMS 37.38
- Support Level
- TELA $1.15
- IGMS $1.17
- Resistance Level
- TELA $1.37
- IGMS $1.31
- Average True Range (ATR)
- TELA 0.19
- IGMS 0.09
- MACD
- TELA -0.10
- IGMS 0.05
- Stochastic Oscillator
- TELA 6.75
- IGMS 32.14
About TELA TELA Bio Inc.
TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, addresses unmet needs in plastic and reconstructive surgery.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.